In the fi rst phase of Cancer Research UK ' s Stratifi ed Medicine Programme, investigators plan to test tumor samples from 9,000 patients who have melanoma, breast, bowel, lung, prostate, and ovarian cancer and who are seen at one of seven National Health Service (NHS) hospitals over the next 2 years. Once patients agree to participate, tumors will be tested for approximately 20 genetic alterations in eight genes. The results of individual tests will be returned to the patients ' physicians, but the data are for research purposes only and not intended to guide therapy. (Traditional NHS programs will continue to administer standardof-care tests approved for clinical care, such as epidermal growth factor receptor [EGFR] testing in lung cancer.)
The goals of the Stratifi ed Medicine Programme are twofold, according to Director James Peach. The fi rst is to improve service delivery of genetic tests within the NHS. The second is to demonstrate that they can capture useful research data from genetic profi ling and routine care data in NHS. "There is a bunch of stuff that the NHS makes more diffi cult," Peach said. "But the one thing the NHS makes easier is a unifi ed bioinformatics solution, and that is what we are trying to do."
The fi rst portion of the work builds on existing systems to improve the quality of genetic tests while reducing their time and cost. "The informatics side -data checking, extraction, and analysis -is a more green fi eld," he said. "Datasets that have been designed either for payment or to facilitate further care may not be checked or defi ned in such a way that would enable them to be used for research," Peach continued. Therefore, the team needs to ensure that the recorded data are accurate and of the right quality for research and are standardized enough for extraction and analysis.
Once those hurdles are overcome, the real power of the project comes from the type of patients most likely to participate. Unlike many clinical trials, which are aimed at patients who do not respond to standard care or who have advanced disease, patients in this project will exhibit all stages of cancer, with many coming in with earlystage, treatable disease. That patient group is relatively untapped as yet, and combining the genetic data with carefully collected patient care data and outcomes should lead to new insights about potential drugs or therapeutic approaches.
As an example, Peach points to the EGFR inhibitors gefi tinib and erlotinib, which were initially targeted at the lung cancer population as a whole but were later found to be effective only in patients with EGFR mutations. He suspects that with the Stratifi ed Medicine data, investigators might see subpopulations that respond to standard drugs and thus improve patient response rates to existing agents, as well as reveal potential new targets for experimental drugs.
The second and third phases of the program aim to integrate the lessons learned from the fi rst phase into standard care and to expand the program to more patients and more cancer types. "We think what is unique about the project we are doing here is the scale," Peach said. If it can eventually be applied to the entire NHS population with millions of cancer patients, it would be "transformational."
Ten Thousand Genotypes in a Year
Meanwhile in Boston, investigators at the Dana -Farber Cancer Institute have established a project called Profi le, designed to genetically test tumors from approximately 10,000 patients each year. Patients will be recruited through the institute itself and through Brigham and Women ' s surgery departments. As with the British program, patients with disease at any stage, or even suspected cancers, are eligible, although many will have more advanced disease by virtue of Dana -Farber ' s status as a tertiary referral center.
The investigators are testing each patient ' s tumor by using the OncoMap multiplex test, which probes 471 mutations in 41 genes. Initially, standard-of-care tests will go through normal channels, and the OncoMap results will be for research purposes only. Patients, though, may have their genetic test results returned to their physicians if they choose to and if the tests fi nd information that merits medical intervention.
"The vast majority of these results are neither medically signifi cant nor actionable, because we don ' t know what they mean yet," said Barrett Rollins, M.D., Ph.D. , chief scientifi c offi cer at DanaFarber and an architect of the program. "That is the point of the research." Rollins says those incidental fi ndings will surely be important for individual patients and their clinicians, but "the real heart of the project is in depositing the results from 10,000 patients per year, year after year, in two enormous data warehouses: all the clinical data into one, and genomics into a separate database."
Creating those databases, and secure means to link them for research queries, was an enormous challenge, according to Rollins. He expects all the effort will pay off. For example, if an investigator wanted to know what the likelihood of response was for a breast cancer patient with a particular mutation who did not respond to trastuzumab, "We ' ll be able to answer that question in about 30 seconds by doing these queries," he said.
